BRPI1014874A2 - piperazinyl azetidinyl heteroaromatic and aromatic amides as monoacylglycerol lipase inhibitors - Google Patents

piperazinyl azetidinyl heteroaromatic and aromatic amides as monoacylglycerol lipase inhibitors

Info

Publication number
BRPI1014874A2
BRPI1014874A2 BRPI1014874A BRPI1014874A BRPI1014874A2 BR PI1014874 A2 BRPI1014874 A2 BR PI1014874A2 BR PI1014874 A BRPI1014874 A BR PI1014874A BR PI1014874 A BRPI1014874 A BR PI1014874A BR PI1014874 A2 BRPI1014874 A2 BR PI1014874A2
Authority
BR
Brazil
Prior art keywords
heteroaromatic
lipase inhibitors
aromatic amides
monoacylglycerol lipase
azetidinyl
Prior art date
Application number
BRPI1014874A
Other languages
Portuguese (pt)
Inventor
Christopher M Flores
Erica L Nulton
Marina I Nelen
Matthew Todd
Stephen Prouty
Sui-Po Zhang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI1014874A2 publication Critical patent/BRPI1014874A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI1014874A 2009-04-22 2010-04-22 piperazinyl azetidinyl heteroaromatic and aromatic amides as monoacylglycerol lipase inhibitors BRPI1014874A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17166109P 2009-04-22 2009-04-22
PCT/US2010/032100 WO2010124122A1 (en) 2009-04-22 2010-04-22 Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors

Publications (1)

Publication Number Publication Date
BRPI1014874A2 true BRPI1014874A2 (en) 2016-04-12

Family

ID=42226535

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014874A BRPI1014874A2 (en) 2009-04-22 2010-04-22 piperazinyl azetidinyl heteroaromatic and aromatic amides as monoacylglycerol lipase inhibitors

Country Status (11)

Country Link
EP (1) EP2421535A1 (en)
JP (1) JP2012524810A (en)
KR (1) KR20120005517A (en)
CN (1) CN102458407B (en)
AU (1) AU2010238746B2 (en)
BR (1) BRPI1014874A2 (en)
CA (1) CA2759706A1 (en)
IL (1) IL215797A0 (en)
RU (1) RU2011147201A (en)
TW (1) TW201103914A (en)
WO (1) WO2010124122A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8987247B2 (en) * 2011-09-30 2015-03-24 Janssen Pharmaceutica Nv Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders
WO2014100834A1 (en) * 2012-12-21 2014-06-26 The Regents Of The University Of California Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity
EP3087067B1 (en) * 2013-12-26 2018-10-24 Takeda Pharmaceutical Company Limited 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors
US10106556B2 (en) 2015-03-30 2018-10-23 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10463753B2 (en) 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
ES2804580T3 (en) 2016-03-31 2021-02-08 Takeda Pharmaceuticals Co Heterocyclic compound
WO2017170830A1 (en) 2016-03-31 2017-10-05 武田薬品工業株式会社 Heterocyclic compound
BR112020005720A2 (en) 2017-09-29 2020-10-20 Takeda Pharmaceutical Company Limited compound or salt, medication, methods for inhibiting monoacylglycerol lipase and for the prophylaxis or treatment of alzheimer's disease, parkinson's disease, huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, anxiety disorder, pain, epilepsy or depression, and, use of compost or salt.
EP3717477B1 (en) 2017-11-28 2022-07-20 F. Hoffmann-La Roche AG New heterocyclic compounds
TW201930300A (en) * 2017-12-15 2019-08-01 瑞士商赫孚孟拉羅股份公司 New heterocyclic compounds
EP3856178B1 (en) 2018-09-28 2026-03-11 Janssen Pharmaceutica NV Monoacylglycerol lipase modulators
MX2022003819A (en) 2019-09-30 2022-05-11 Janssen Pharmaceutica Nv RADIOLABELLED MGL PET LIGANDS.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2915199B1 (en) * 2007-04-18 2010-01-22 Sanofi Aventis TRIAZOLOPYRIDINE-CARBOXAMIDE AND TRIAZOLOPYRIMIDINE-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
EP2180048B1 (en) * 2008-10-09 2014-12-17 Janssen Pharmaceutica N.V. Alternative crystal form of monoacylglycerol lipase (MGLL)

Also Published As

Publication number Publication date
RU2011147201A (en) 2013-05-27
WO2010124122A1 (en) 2010-10-28
EP2421535A1 (en) 2012-02-29
CN102458407B (en) 2014-03-05
JP2012524810A (en) 2012-10-18
AU2010238746A1 (en) 2011-11-10
CN102458407A (en) 2012-05-16
KR20120005517A (en) 2012-01-16
TW201103914A (en) 2011-02-01
AU2010238746B2 (en) 2015-02-19
IL215797A0 (en) 2012-01-31
CA2759706A1 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
BRPI1014888A2 (en) piperazinyl azetidinyl heteroaromatic and aromatic amides as monoacylglycerol lipase inhibitors
BRPI1014874A2 (en) piperazinyl azetidinyl heteroaromatic and aromatic amides as monoacylglycerol lipase inhibitors
BRPI1014281A2 (en) azetidinyl diamides as monoacylglycerol lipase inhibitors
IL225769A0 (en) Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors
BR112012028883A2 (en) liquid supply and method
HRP20190016T1 (en) HETEROCYCLIC COMPOUNDS AND THEIR USE
IL225815A0 (en) Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
HRP20160737T1 (en) ANTI-HER3-ANTIBODIES AND THEIR USES
ZA201202489B (en) Novel heterocyclic acrylamides and their use as pharmaceuticals
PT3650125T (en) LIQUID AND METHODS ATOMIZER
PL2427416T3 (en) Substituted AROMATIC COMPOUNDS AND THEIR PHARMACEUTICAL APPLICATIONS
FI20090142A0 (en) New methods and products
FI20090357L (en) Method and arrangement
DE11786796T8 (en) ANTIGENPEPTIDE AND USE THEREOF
AP3650A (en) Apolipoprotein l-i variants and their use
GB201012950D0 (en) Stabiliser and assembly
BR112013012843A2 (en) nutrient supply compositions and methods
FI20105760L (en) Method and arrangement
EP2535415A4 (en) Modified nucleotide molecules of xylanase and application thereof
EP2638160A4 (en) NUCLIONS AND RIBOCAPSIDES
FI20105798L (en) Conveyor track and space arrangement
DE112011104090A5 (en) Radfelgengetriebe and Planetenumlaufgetriebe
ES1070486Y (en) MODULAR AND SELF-PLACABLE PALE
FI20096360A0 (en) BIOLIMENTS AND WOODBOARD
ES1072059Y (en) PRE-DRYING PALETTE AND / OR MASSAGE

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]